We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lantheus Holdings (LNTH) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Lantheus Holdings (LNTH - Free Report) closed at $83.92 in the latest trading session, marking a +1.17% move from the prior day. This change lagged the S&P 500's 1.23% gain on the day. At the same time, the Dow added 0.84%, and the tech-heavy Nasdaq lost 2.24%.
Heading into today, shares of the diagnostic imaging company had lost 6.88% over the past month, lagging the Medical sector's gain of 2.55% and the S&P 500's gain of 4.67% in that time.
Wall Street will be looking for positivity from Lantheus Holdings as it approaches its next earnings report date. The company is expected to report EPS of $1.33, up 49.44% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $306.68 million, up 37.08% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.60 per share and revenue of $1.26 billion. These totals would mark changes of +32.7% and +34.62%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Lantheus Holdings. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Lantheus Holdings is holding a Zacks Rank of #1 (Strong Buy) right now.
Digging into valuation, Lantheus Holdings currently has a Forward P/E ratio of 14.81. For comparison, its industry has an average Forward P/E of 24.35, which means Lantheus Holdings is trading at a discount to the group.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 65, putting it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Lantheus Holdings (LNTH) Gains But Lags Market: What You Should Know
Lantheus Holdings (LNTH - Free Report) closed at $83.92 in the latest trading session, marking a +1.17% move from the prior day. This change lagged the S&P 500's 1.23% gain on the day. At the same time, the Dow added 0.84%, and the tech-heavy Nasdaq lost 2.24%.
Heading into today, shares of the diagnostic imaging company had lost 6.88% over the past month, lagging the Medical sector's gain of 2.55% and the S&P 500's gain of 4.67% in that time.
Wall Street will be looking for positivity from Lantheus Holdings as it approaches its next earnings report date. The company is expected to report EPS of $1.33, up 49.44% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $306.68 million, up 37.08% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.60 per share and revenue of $1.26 billion. These totals would mark changes of +32.7% and +34.62%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Lantheus Holdings. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Lantheus Holdings is holding a Zacks Rank of #1 (Strong Buy) right now.
Digging into valuation, Lantheus Holdings currently has a Forward P/E ratio of 14.81. For comparison, its industry has an average Forward P/E of 24.35, which means Lantheus Holdings is trading at a discount to the group.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 65, putting it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.